Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp announces FDA approval of OTEZLA


Friday, 21 Mar 2014 03:40pm EDT 

Celgene Corp:Says the U.S. Food and Drug Administration (FDA) approves OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis. 

Company Quote

109.6
3.48 +3.28%
24 Dec 2014